Pfizer Says Results Positive in Rheumatoid Arthritis Study

Date : 06/12/2019 @ 1:58PM
Source : Dow Jones News
Stock : Pfizer, Inc. (PFE)
Quote : 43.06  0.32 (0.75%) @ 10:46PM

Pfizer Says Results Positive in Rheumatoid Arthritis Study

Pfizer (NYSE:PFE)
Historical Stock Chart

2 Months : From May 2019 to Jul 2019

Click Here for more Pfizer Charts.

By Michael Dabaie


Pfizer Inc. (PFE) said results were positive from a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis.

Patients who achieved low disease activity with Xeljanz extended release 11 mg once daily plus methotrexate after a 24-week open-label run-in period, were randomized to evaluate the efficacy and safety of Xeljanz as monotherapy. The study demonstrated non-inferiority of methotrexate withdrawal with Xeljanz at week 48, Pfizer said.

The study results will be presented during a late-breaking oral session at the Annual European Congress of Rheumatology in Madrid on June 15.


Write to Michael Dabaie at


(END) Dow Jones Newswires

June 12, 2019 08:43 ET (12:43 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest PFE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.